Search results
Results from the WOW.Com Content Network
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. [1] It acts against interleukin 31 (IL-31), [2] which is a cytokine involved in causing itchiness (pruritus). [2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. [3]
1.10 Platinum compounds: Carboplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Ovarian cancer, lung cancer and squamous cell head and neck cancer: Myelosuppression, nausea and vomiting (30-90%), peripheral neuropathy, ototoxicity, anaphylaxis, acute kidney failure (rare), haemolytic uraemic syndrome (rare) and loss of ...
[9] [10] [11] Its efficacy equals that of prednisolone at first, though oclacitinib has been found to be more effective in the short term in terms of itchiness and dermatitis, long term safety is unknown. [12] It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine. [10] [13]
The PRISMA flow diagram, depicting the flow of information through the different phases of a systematic review. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is an evidence-based minimum set of items aimed at helping scientific authors to report a wide array of systematic reviews and meta-analyses, primarily used to assess the benefits and harms of a health care ...
Created Date: 8/30/2012 4:52:52 PM
Currently approved checkpoint inhibitors target the molecules CTLA4, PD-1, and PD-L1. PD-1 is the transmembrane programmed cell death 1 protein (also called PDCD1 and CD279), which interacts with PD-L1 (PD-1 ligand 1, or CD274). PD-L1 on the cell surface binds to PD-1 on an immune cell surface, which inhibits immune cell activity.
Zoetis Inc. (/zō-EH-tis/ [4]) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. [5] [4] [6] The company was a subsidiary of Pfizer, [7] the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company.
A review of several treatments found that azathioprine, interferon alpha and methotrexate were not effective. [41] Cyclophosphamide and rituximab seem to have some response. Mycophenolate mofetil may be of use in milder cases. Immunoglobulin and steroids are the first line choices for treatment. [citation needed]